We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Corticosteroids Slash COPD Deaths

By HospiMedica staff writers
Posted on 05 Sep 2005
The outcomes of two new studies have revealed that patients with chronic obstructive pulmonary disease (COPD) who used inhaled corticosteroids (ICS) experienced a 30% reduction in risk for either rehospitalization or death from COPD.

In an effort to avoid "immortal time bias,” the researchers created two matched sets of patients, based on a cohort from the General Practice Database (London, UK). More...
This database is the world's largest computed database of anonymized longitudinal medical records on primary care. All patients had been hospitalized for a COPD-related condition from 1990-1999. In the first study, each group of matched patients numbered 393. One set was treated with ICS and the other was untreated. In the second study, a case-control analysis of 2,222 patients was designed without regard to ICS exposure. Both studies resulted in a reduction of about 30% in the risk for either death or hospitalization.

COPD is now the fourth leading cause of death worldwide, causing more than 2.5 million deaths per year. COPD is characterized by airflow obstruction that interferes with normal breathing. The two most frequent disease conditions covered by the COPD category are severe emphysema and chronic bronchitis.

The findings were reported in the August 15, 2005, issue of the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. The research was led by Victor A. Kiri, Ph.D., worldwide epidemiology, GlaxoSmithKline (London, UK).




Related Links:
General Practice Database

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.